These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 12809837)

  • 1. Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride.
    Miller DP; Alfredson T; Cook SF; Sands BE; Walker AM
    Am J Gastroenterol; 2003 May; 98(5):1117-22. PubMed ID: 12809837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences.
    Chang L; Tong K; Ameen V
    Am J Gastroenterol; 2010 Apr; 105(4):866-75. PubMed ID: 20197759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective.
    Lewis JH
    Expert Rev Gastroenterol Hepatol; 2010 Feb; 4(1):13-29. PubMed ID: 20136586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients.
    Wolfe SG; Chey WY; Washington MK; Harding J; Heath AT; McSorley DJ; Dukes GE; Hunt CM
    Am J Gastroenterol; 2001 Mar; 96(3):803-11. PubMed ID: 11280555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
    Rahimi R; Nikfar S; Abdollahi M
    Clin Ther; 2008 May; 30(5):884-901. PubMed ID: 18555935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Occurrence of colon ischemia in relation to irritable bowel syndrome.
    Cole JA; Cook SF; Sands BE; Ajene AN; Miller DP; Walker AM
    Am J Gastroenterol; 2004 Mar; 99(3):486-91. PubMed ID: 15056090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.
    Krause R; Ameen V; Gordon SH; West M; Heath AT; Perschy T; Carter EG
    Am J Gastroenterol; 2007 Aug; 102(8):1709-19. PubMed ID: 17509028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Algorithms to identify colonic ischemia, complications of constipation and irritable bowel syndrome in medical claims data: development and validation.
    Sands BE; Duh MS; Cali C; Ajene A; Bohn RL; Miller D; Cole JA; Cook SF; Walker AM
    Pharmacoepidemiol Drug Saf; 2006 Jan; 15(1):47-56. PubMed ID: 15915441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome.
    Lembo T; Wright RA; Bagby B; Decker C; Gordon S; Jhingran P; Carter E;
    Am J Gastroenterol; 2001 Sep; 96(9):2662-70. PubMed ID: 11569692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.
    Chey WD; Chey WY; Heath AT; Dukes GE; Carter EG; Northcutt A; Ameen VZ
    Am J Gastroenterol; 2004 Nov; 99(11):2195-203. PubMed ID: 15555002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alosetron: ischemic colitis and serious complications of constipation.
    Gallo-Torres H; Brinker A; Avigan M
    Am J Gastroenterol; 2006 May; 101(5):1080-3. PubMed ID: 16696787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome.
    Viramontes BE; Camilleri M; McKinzie S; Pardi DS; Burton D; Thomforde GM
    Am J Gastroenterol; 2001 Sep; 96(9):2671-6. PubMed ID: 11569693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.
    Chang L; Ameen VZ; Dukes GE; McSorley DJ; Carter EG; Mayer EA
    Am J Gastroenterol; 2005 Jan; 100(1):115-23. PubMed ID: 15654790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome.
    Watson ME; Lacey L; Kong S; Northcutt AR; McSorley D; Hahn B; Mangel AW
    Am J Gastroenterol; 2001 Feb; 96(2):455-9. PubMed ID: 11232690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome.
    Olden K; DeGarmo RG; Jhingran P; Bagby B; Decker C; Markowitz M; Carter E; Bobbitt W; Dahdul A; DeCastro E; Gringeri L; Johanson J; Levinson L; Mula G; Poleynard G; Stoltz RR; Truesdale R; Young D;
    Am J Gastroenterol; 2002 Dec; 97(12):3139-46. PubMed ID: 12492201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic features.
    Stewart WF; Liberman JN; Sandler RS; Woods MS; Stemhagen A; Chee E; Lipton RB; Farup CE
    Am J Gastroenterol; 1999 Dec; 94(12):3530-40. PubMed ID: 10606315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ischemic colitis during treatment with alosetron.
    Friedel D; Thomas R; Fisher RS
    Gastroenterology; 2001 Feb; 120(2):557-60. PubMed ID: 11159896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron.
    Bellini M; Rappelli L; Blandizzi C; Costa F; Stasi C; Colucci R; Giannaccini G; Marazziti D; Betti L; Baroni S; Mumolo MG; Marchi S; Del Tacca M
    Am J Gastroenterol; 2003 Dec; 98(12):2705-11. PubMed ID: 14687821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.
    Camilleri M; Northcutt AR; Kong S; Dukes GE; McSorley D; Mangel AW
    Lancet; 2000 Mar; 355(9209):1035-40. PubMed ID: 10744088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overlapping upper and lower gastrointestinal symptoms in irritable bowel syndrome patients with constipation or diarrhea.
    Talley NJ; Dennis EH; Schettler-Duncan VA; Lacy BE; Olden KW; Crowell MD
    Am J Gastroenterol; 2003 Nov; 98(11):2454-9. PubMed ID: 14638348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.